- Markets
- Healthcare
- BAFNAPH
BAFNAPH
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Bafna Pharmaceuticals Says Commercial Production At Co's Manufacturing Facilities In Chennai, Tamil Nadu Started
Dec 8 (Reuters) - Bafna Pharmaceuticals Ltd BAFP.NS:
COMMERCIAL PRODUCTION AT CO'S MANUFACTURING FACILITIES IN CHENNAI, TAMIL NADU STARTED
DUE TO IMPACT OF “MICHAUNG” CYCLONE CO'S MANUFACTURING FACILITIES IN CHENNAI, TAMIL NADU WAS FLOODED/ WATERLOGGED
PRODUCTION ACTIVITIES WERE DISRUPTED FROM DEC. 04, 2023
Source text for Eikon: ID:nBSE9cMkWj
Further company coverage: BAFP.NS
(([email protected];))
Dec 8 (Reuters) - Bafna Pharmaceuticals Ltd BAFP.NS:
COMMERCIAL PRODUCTION AT CO'S MANUFACTURING FACILITIES IN CHENNAI, TAMIL NADU STARTED
DUE TO IMPACT OF “MICHAUNG” CYCLONE CO'S MANUFACTURING FACILITIES IN CHENNAI, TAMIL NADU WAS FLOODED/ WATERLOGGED
PRODUCTION ACTIVITIES WERE DISRUPTED FROM DEC. 04, 2023
Source text for Eikon: ID:nBSE9cMkWj
Further company coverage: BAFP.NS
(([email protected];))
Bafna Pharmaceuticals Says Due To Torrential Rains of Michaung Cyclone, Co's Manufacturing Facilities In Chennai Was Totally Flooded
Dec 7 (Reuters) - Bafna Pharmaceuticals Ltd BAFP.NS:
DUE TO TORRENTIAL RAINSOF MICHAUNG CYCLONE, CO'S MANUFACTURING FACILITIES IN CHENNAI WAS TOTALLY FLOODED
PRODUCTION ACTIVITIES HAVE BEEN DISRUPTED FROM DEC 4
Source text for Eikon: ID:nBSE8DxK5X
Further company coverage: BAFP.NS
(([email protected];))
Dec 7 (Reuters) - Bafna Pharmaceuticals Ltd BAFP.NS:
DUE TO TORRENTIAL RAINSOF MICHAUNG CYCLONE, CO'S MANUFACTURING FACILITIES IN CHENNAI WAS TOTALLY FLOODED
PRODUCTION ACTIVITIES HAVE BEEN DISRUPTED FROM DEC 4
Source text for Eikon: ID:nBSE8DxK5X
Further company coverage: BAFP.NS
(([email protected];))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Bafna Pharma do?
Bafna Pharmaceuticals Ltd specializes in manufacturing tablets, capsules, and oral syrups, focusing on prescription drugs for the global market. They offer contract manufacturing services and a wide range of pharmaceutical categories.
Who are the competitors of Bafna Pharma?
Bafna Pharma major competitors are Krebs Biochem.&Inds, IndoAmerican Advance, Bal Pharma, Amwill Health Care, Syschem (India), Vaishali Pharma, Auro Laboratories. Market Cap of Bafna Pharma is ₹180 Crs. While the median market cap of its peers are ₹171 Crs.
Is Bafna Pharma financially stable compared to its competitors?
Bafna Pharma seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Bafna Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Bafna Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Bafna Pharma allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Inventory
How strong is Bafna Pharma balance sheet?
Balance sheet of Bafna Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Bafna Pharma improving?
No, profit is decreasing. The profit of Bafna Pharma is ₹4.3 Crs for TTM, ₹7.35 Crs for Mar 2024 and ₹11.34 Crs for Mar 2023.
Is the debt of Bafna Pharma increasing or decreasing?
Yes, The debt of Bafna Pharma is increasing. Latest debt of Bafna Pharma is ₹21.6 Crs as of Mar-24. This is greater than Mar-23 when it was ₹7.31 Crs.
Is Bafna Pharma stock expensive?
Bafna Pharma is not expensive. Latest PE of Bafna Pharma is 41.79, while 3 year average PE is 90.32. Also latest EV/EBITDA of Bafna Pharma is 15.94 while 3yr average is 26.67.
Has the share price of Bafna Pharma grown faster than its competition?
Bafna Pharma has given better returns compared to its competitors. Bafna Pharma has grown at ~14.48% over the last 7yrs while peers have grown at a median rate of 9.0%
Is the promoter bullish about Bafna Pharma?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Bafna Pharma is 75.0% and last quarter promoter holding is 88.3%
Are mutual funds buying/selling Bafna Pharma?
There is Insufficient data to gauge this.